UK markets open in 4 hours 46 minutes

Adocia SA (ADOCY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
11.800.00 (0.00%)
At close: 10:06AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.80
BidN/A x N/A
AskN/A x N/A
Day's range11.80 - 11.80
52-week range9.60 - 13.22
Avg. volume4
Market cap82.526M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-3.66
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

    This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to AdociaBC Lispro addresses the Chinese prandial insulin market which is approx. $1.4bn today with double-digit growth LYON, France, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatments and other metab

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of September 30th, 2021

    LYON, France, October 12, 2021--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative formula

  • Business Wire

    Adocia Announces Oral Presentation Reviewing M1Pram (ADO09) at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD)

    LYON, France, September 21, 2021--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that it will deliver an oral presentation covering proprietary M1Pram (ADO09) pramlintide insulin at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD), being held virtually du